genel tıp derg Genel Tıp Dergisi 2602-3741 Selcuk University Periferal Lökositlerde CD35, CD46, CD55 ve CD59 Düzeyleri Kurtoğlu Ayşegül Uğur Antalya Eğitim ve Araştırma Hastanesi, Tıbbi Biyokimya Kliniği, Antalya Uğur Sevcan Akdeniz Üniversitesi, Tıp Fakültesi, Romatoloji Bilim Dalı, Antalya Koçtekin Belkıs Antalya Eğitim ve Araştırma Hastanesi, Kan Merkezi, Antalya Karagül Aydan Antalya Eğitim ve Araştırma Hastanesi, Tıbbi Mikrobiyoloji Kliniği, Antalya 03 01 2017 27 1 23 27 Copyright © 1990, Genel Tıp Dergisi 1990 Genel Tıp Dergisi

Giriş: Kompleman aktivasyonunun, hedef molekül dışında bulunan çevre dokulara zarar vermesini kompleman düzenleyici proteinler engeller. Özellikle CD35, CD46, CD55 ve CD59 hastalıklarla ilişkilendirilen kompleman düzenleyici proteinlerdir. Bu proteinlerin genetik varyasyonlarına bağlı olarak enfeksiyon, tromboz, otoimmun hastalıkların oluştuğu bir çok çalışma bulunmaktadır. Çalışmamızda sağlıklı Türk toplumunda periferal lökositlerde CD35, CD46, CD55 ve CD59 proteinlerinin ekspresyon düzeylerini ölçtük.Gereç ve Yöntem: Çalışma yaşları 17-39 arasında değişen, 20 sağlıklı gönüllüde yapıldı. Alınan kan örnekleri CD35, CD46, CD55 ve CD59 antikorları kullanılarak, 1 saat içinde flow sitometrik olarak analiz edildi. CD35, CD46, CD55 ve CD59’u pozitif bulunan nötrofil, monosit ve lenfositler % olarak belirtildi.Bulgular: CD35 düzeyinin en fazla nötrofillerde %92 , monosit %84 ve en az oranda da lenfositlerde %17 olduğu gözlendi. CD35 düzeyi lenfositlerde, monosit ve nötrofile göre anlamlı derecede düşük tespit edildi p

Objective: Complement regulatory proteins prevent the harmful effects of complement activation to the surrounding tissues other than target molecule. Particularly CD35, CD46, CD55, and CD59 are complement regulatory proteins that are related to diseases. Many studies were reported infectious, thrombotic, and autoimmune diseases developing due to genetic variations of these proteins. In this study we measured the expression levels of CD35, CD46, CD55, and CD59 on peripheral leucocytes in healthy Turkish population.Materials and Methods: The study was held in 20 healthy volunteers whose ages range from 17 to 39. Blood samples were analysed by flow cytometry within one hour by using CD35, CD46, CD55, and CD59 antibodies. CD35, CD46, CD55, and CD59 positive neutrophils, monocytes, lymphocytes were mentioned as percentages.Results: The highest CD35 level was found on neutrophils 92% , monocytes 84% and the lymphocytes were the least 17% . CD35 levels were significantly lower on lymphocytes, compared to monocytes and neutrophils p

 Kompleman düzenleyici proteinler sağlıklı populasyon periferal lökositler Complement regulatory proteins healhty population peripheral leucocytes Kristina A. Stoermer, Thomas E. Morrison. Complement and Viral Pathogenesis. Virology 2011; 411: 362–73. Michael C. Carroll. Complement and Humoral Immunity. Vaccine 2008; 26: 128-33. Ricklin D,Hajishengallis G, Yang K et al. Complement - a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785–97. Java A, Liszewski MK, Hourcade DE et al. Role of comple- ment receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney. Mol Immunol 2015;67:584-95. Yamamoto H, Fara AF, Dasgupta P, et al. CD46: the 'mul- titasker' of complement proteins. Int J Biochem Cell Biol 2013;45:2808-20. Ferrer MF, Scharrig E, Alberdi L, et al. Decay-Accelerating Factor 1 Deficiency Exacerbates Leptospiral-Induced Mu- rine Chronic Nephritis and Renal Fibrosis. PLoS One 2014; 9: e102860. Cai B, Xie S, Liu F, et al.Rapid Degradation of the Comp- lement Regulator, CD59, by a Novel Inhibitor. J Biol Chem 2014; 289:12109-25. Watson R,Wearmouth E, McLoughlin AC, et al. Autoanti- bodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015; 63: 287-96. DeZern AE, Brodsky RA.Paroxysmal nocturnal hemoglo- binuria: a complement-mediated hemolytic anemia. Hema- tol Oncol Clin North Am 2015;29:479-94. Cicardi M, Bork K, Caballero T, et al.Evidence-based re- commendations for the therapeutic management of angi- oedema owing to hereditary C1 inhibitor deficiency: con- sensus report of an International Working Group. Allergy 2012;67:147-57. Wang Q, Zhao HS, Li L. Association between complement factor I gene polymorphisms and the risk of age-related macular degeneration: a Meta-analysis of literature. Int J Ophthalmol 2016;3:298-305. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plas- modium falciparum rosetting confers protection against severe malaria.Proc Natl Acad Sci U S A. 2004;101:272-7. Kalunian KC, Chatham WW, Massarotti EM, et al. Mea- surement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythe- matosus. Arthritis Rheum 2012;64:4040-7. Klaska I, Nowak JZ. The role of complement in physi- ology and pathology. Postepy Hig Med Dosw (Online) 2007;61:167-77. Melhorn MI, Brodsky AS, Estanislau J, et al. CR1-mediated ATP release by human red blood cells promotes CR1 clus- tering and modulates the immune transfer process. J Biol Chem 2013;288:31139-53. Birmingham DJ, Irshaid F, Gavit KF, et al. polymorphism in the type one complement receptor (CR1) involves an ad- ditional cysteine within the C3b/C4b binding domain that inhibits ligand binding. Mol Immunol 2007; 44: 3510-16. Zhu XC, Yu JT, Jiang T, et al. CR1 in Alzheimer's disease. Mol Neurobiol 2015;55:753-65. Opi DH, Uyoga S, Orori EN, et al. Red blood cell comp- lement receptor one level varies with Knops blood group, α+thalassaemia and age among Kenyan children. Genes Immun 2016;17:171-8. Kalunian KC, Chatham WW, Massarotti EM, et al. Mea- surement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythe- matosus. Arthritis Rheum 2012;64:440-7. Liszewski MK, Kemper C, Price JD, et al.Emerging roles and new functions of CD46. Springer Semin Immunopat- hol 2005;27:345-58. Liszewski MK, Atkinson JP.Complement regulator CD46: genetic variants and disease associations. Hum Genomics 2015;9:7. Clifford HD, Hayden CM, Khoo SK, et al.CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive Australian children. Clin Vaccine Immunol 2012;19:704- 10. Obaid JM, Abo El-Nazar SY, Ghanem AM, et al. Expression of CD55 on red blood cells of β-thalassemia patients. He- moglobin. 2014;38:339-44. Karpus ON, Kiener HP, Niederreiter B, et al. CD55 depo- sited on synovial collagen fibers protects from immune complex-mediated arthritis. Arthritis Res Ther;17:6. doi: 10.1186/s13075-015-0518-4. Riabi S, Harrath R, Gaaloul I, et al. Study of Coxsackie B viruses interactions with Coxsackie Adenovirus receptor and Decay-Accelerating Factor using Human CaCo-2 cell line. J Biomed Sci. 2014 May 21;21:50. doi: 10.1186/1423- 0127-21-50. Zhou J, To KK, Dong H, et al. A functional variation in CD55 increases the severity of 2009 pandemic H1N1 influ- enza A virus infection. J Infect Dis;206:495-503. Hamdoon MN, Fattouh M, El-Din AN, et al. The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the developmentof autoimmune myasthenia gravis.Electron Physician 2016;8:1718-26. Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal comple- ment complexes. Immunol Res 2011;51:45-60. Brodsky RA.Complement in hemolytic anemia. Blood 2015; 126:2459-65. Wang W, Wang X, Yang L, et al. Modulation of host CD59 expression by varicella-zoster virus in human xenografts in vivo. Virology 2016;491:96-105.